266 related articles for article (PubMed ID: 31406254)
41. Clinico-Genomic Profiling of Conventional and Dedifferentiated Chondrosarcomas Reveals TP53 Mutation to Be Associated with Worse Outcomes.
Denu RA; Yang RK; Lazar AJ; Patel SS; Lewis VO; Roszik J; Livingston JA; Wang WL; Shaw KR; Ratan R; Zarzour MA; Bird J; Raza S; Akdemir KC; Rodon Ahnert J; Subbiah V; Patel S; Conley AP
Clin Cancer Res; 2023 Dec; 29(23):4844-4852. PubMed ID: 37747813
[TBL] [Abstract][Full Text] [Related]
42. Isocitrate dehydrogenase mutation as a therapeutic target in gliomas.
Han CH; Batchelor TT
Chin Clin Oncol; 2017 Jun; 6(3):33. PubMed ID: 28705010
[TBL] [Abstract][Full Text] [Related]
43. Inhibitors of Mutant Isocitrate Dehydrogenases 1 and 2 (mIDH1/2): An Update and Perspective.
Ma T; Zou F; Pusch S; Xu Y; von Deimling A; Zha X
J Med Chem; 2018 Oct; 61(20):8981-9003. PubMed ID: 29847930
[TBL] [Abstract][Full Text] [Related]
44. Targeting glutaminolysis in chondrosarcoma in context of the IDH1/2 mutation.
Peterse EFP; Niessen B; Addie RD; de Jong Y; Cleven AHG; Kruisselbrink AB; van den Akker BEWM; Molenaar RJ; Cleton-Jansen AM; Bovée JVMG
Br J Cancer; 2018 Apr; 118(8):1074-1083. PubMed ID: 29576625
[TBL] [Abstract][Full Text] [Related]
45. Identification and Characterization of Small-Molecule Inhibitors of the R132H/R132H Mutant Isocitrate Dehydrogenase 1 Homodimer and R132H/Wild-Type Heterodimer.
Brooks E; Wu X; Hanel A; Nguyen S; Wang J; Zhang JH; Harrison A; Zhang W
J Biomol Screen; 2014 Sep; 19(8):1193-200. PubMed ID: 24980596
[TBL] [Abstract][Full Text] [Related]
46. Efficient induction of differentiation and growth inhibition in IDH1 mutant glioma cells by the DNMT Inhibitor Decitabine.
Turcan S; Fabius AW; Borodovsky A; Pedraza A; Brennan C; Huse J; Viale A; Riggins GJ; Chan TA
Oncotarget; 2013 Oct; 4(10):1729-36. PubMed ID: 24077826
[TBL] [Abstract][Full Text] [Related]
47. To be Wild or Mutant: Role of Isocitrate Dehydrogenase 1 (IDH1) and 2-Hydroxy Glutarate (2-HG) in Gliomagenesis and Treatment Outcome in Glioma.
Bhavya B; Anand CR; Madhusoodanan UK; Rajalakshmi P; Krishnakumar K; Easwer HV; Deepti AN; Gopala S
Cell Mol Neurobiol; 2020 Jan; 40(1):53-63. PubMed ID: 31485826
[TBL] [Abstract][Full Text] [Related]
48. Isoform Switching as a Mechanism of Acquired Resistance to Mutant Isocitrate Dehydrogenase Inhibition.
Harding JJ; Lowery MA; Shih AH; Schvartzman JM; Hou S; Famulare C; Patel M; Roshal M; Do RK; Zehir A; You D; Selcuklu SD; Viale A; Tallman MS; Hyman DM; Reznik E; Finley LWS; Papaemmanuil E; Tosolini A; Frattini MG; MacBeth KJ; Liu G; Fan B; Choe S; Wu B; Janjigian YY; Mellinghoff IK; Diaz LA; Levine RL; Abou-Alfa GK; Stein EM; Intlekofer AM
Cancer Discov; 2018 Dec; 8(12):1540-1547. PubMed ID: 30355724
[TBL] [Abstract][Full Text] [Related]
49. Metabolism, Activity, and Targeting of D- and L-2-Hydroxyglutarates.
Ye D; Guan KL; Xiong Y
Trends Cancer; 2018 Feb; 4(2):151-165. PubMed ID: 29458964
[TBL] [Abstract][Full Text] [Related]
50. Induction of sarcomas by mutant IDH2.
Lu C; Venneti S; Akalin A; Fang F; Ward PS; Dematteo RG; Intlekofer AM; Chen C; Ye J; Hameed M; Nafa K; Agaram NP; Cross JR; Khanin R; Mason CE; Healey JH; Lowe SW; Schwartz GK; Melnick A; Thompson CB
Genes Dev; 2013 Sep; 27(18):1986-98. PubMed ID: 24065766
[TBL] [Abstract][Full Text] [Related]
51. Molecular Pathways: Isocitrate Dehydrogenase Mutations in Cancer.
Clark O; Yen K; Mellinghoff IK
Clin Cancer Res; 2016 Apr; 22(8):1837-42. PubMed ID: 26819452
[TBL] [Abstract][Full Text] [Related]
52. Recent advances of IDH1 mutant inhibitor in cancer therapy.
Tian W; Zhang W; Wang Y; Jin R; Wang Y; Guo H; Tang Y; Yao X
Front Pharmacol; 2022; 13():982424. PubMed ID: 36091829
[TBL] [Abstract][Full Text] [Related]
53. IDH1 mutation contributes to myeloid dysplasia in mice by disturbing heme biosynthesis and erythropoiesis.
Gu Y; Yang R; Yang Y; Zhao Y; Wakeham A; Li WY; Tseng A; Leca J; Berger T; Saunders M; Fortin J; Gao X; Yuan Y; Xiao L; Zhang F; Zhang L; Gao G; Zhou W; Wang Z; Mak TW; Ye J
Blood; 2021 Feb; 137(7):945-958. PubMed ID: 33254233
[TBL] [Abstract][Full Text] [Related]
54. Isocitrate dehydrogenase 1 (IDH1) mutation in breast adenocarcinoma is associated with elevated levels of serum and urine 2-hydroxyglutarate.
Fathi AT; Sadrzadeh H; Comander AH; Higgins MJ; Bardia A; Perry A; Burke M; Silver R; Matulis CR; Straley KS; Yen KE; Agresta S; Kim H; Schenkein DP; Borger DR
Oncologist; 2014 Jun; 19(6):602-7. PubMed ID: 24760710
[TBL] [Abstract][Full Text] [Related]
55. Allosteric Mutant IDH1 Inhibitors Reveal Mechanisms for IDH1 Mutant and Isoform Selectivity.
Xie X; Baird D; Bowen K; Capka V; Chen J; Chenail G; Cho Y; Dooley J; Farsidjani A; Fortin P; Kohls D; Kulathila R; Lin F; McKay D; Rodrigues L; Sage D; Touré BB; van der Plas S; Wright K; Xu M; Yin H; Levell J; Pagliarini RA
Structure; 2017 Mar; 25(3):506-513. PubMed ID: 28132785
[TBL] [Abstract][Full Text] [Related]
56. In vivo efficacy of mutant IDH1 inhibitor HMS-101 and structural resolution of distinct binding site.
Chaturvedi A; Goparaju R; Gupta C; Weder J; Klünemann T; Araujo Cruz MM; Kloos A; Goerlich K; Schottmann R; Othman B; Struys EA; Bähre H; Grote-Koska D; Brand K; Ganser A; Preller M; Heuser M
Leukemia; 2020 Feb; 34(2):416-426. PubMed ID: 31586149
[TBL] [Abstract][Full Text] [Related]
57. Targeted Next-Generation Sequencing Identifies Molecular and Genetic Events in Dedifferentiated Chondrosarcoma.
Lucas CG; Grenert JP; Horvai A
Arch Pathol Lab Med; 2021 Aug; 145(8):1009-1017. PubMed ID: 33147331
[TBL] [Abstract][Full Text] [Related]
58. IDH1/2 Mutations in Cancer Stem Cells and Their Implications for Differentiation Therapy.
Molenaar RJ; Wilmink JW
J Histochem Cytochem; 2022 Jan; 70(1):83-97. PubMed ID: 34967233
[TBL] [Abstract][Full Text] [Related]
59. In vivo anti-tumor effect of PARP inhibition in IDH1/2 mutant MDS/AML resistant to targeted inhibitors of mutant IDH1/2.
Gbyli R; Song Y; Liu W; Gao Y; Biancon G; Chandhok NS; Wang X; Fu X; Patel A; Sundaram R; Tebaldi T; Mamillapalli P; Zeidan AM; Flavell RA; Prebet T; Bindra RS; Halene S
Leukemia; 2022 May; 36(5):1313-1323. PubMed ID: 35273342
[TBL] [Abstract][Full Text] [Related]
60. Vitamin C in combination with inhibition of mutant IDH1 synergistically activates TET enzymes and epigenetically modulates gene silencing in colon cancer cells.
Gerecke C; Schumacher F; Berndzen A; Homann T; Kleuser B
Epigenetics; 2020 Mar; 15(3):307-322. PubMed ID: 31505989
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]